Related references
Note: Only part of the references are listed.Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study
Amanda Frisosky Abuaf et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)
Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East
Raed Alroughani et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2022)
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study
Roberta Lanzillo et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population
Eva Fernandez-Diaz et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
COVID-19 in ocrelizumab-treated people with multiple sclerosis
Richard Hughes et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Real-world experience of ocrelizumab in multiple sclerosis in an Arab population
Beatriz Garcia-Canibano et al.
JOURNAL OF DRUG ASSESSMENT (2021)
Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study
Kyle Smoot et al.
BMJ NEUROLOGY OPEN (2021)
Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
Juan Ignacio Rojas et al.
ARQUIVOS DE NEURO-PSIQUIATRIA (2021)
Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines
B. Yamout et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Ocrelizumab initiation in patients with MS A multicenter observational study
Erik Ellwardt et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients
Victoria Prockl et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)
Five years of ocrelizumab in relapsing multiple sclerosis OPERA studies open-label extension
Stephen L. Hauser et al.
NEUROLOGY (2020)
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
Benjamin Turner et al.
JOURNAL OF NEUROLOGY (2019)
Data quality evaluation for observational multiple sclerosis registries
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Data quality evaluation for observational multiple sclerosis registries
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function
Daniel Ontaneda et al.
LANCET (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
Per Soelberg Sorensen et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2016)
Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy
Rui Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Disease Activity Free Status A New End Point for a New Era in Multiple Sclerosis Clinical Research?
Carolyn J. Bevan et al.
JAMA NEUROLOGY (2014)
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
Christian Klein et al.
MABS (2013)
Disease activity free status in MS
Fred D. Lublin
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Pediatric Multiple Sclerosis
Tanuja Chitnis et al.
NEUROLOGIC CLINICS (2011)
Clinical features and viral serologies in children with multiple a multinational observational study
Brenda Banwell et al.
LANCET NEUROLOGY (2007)
Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients
J Río et al.
ANNALS OF NEUROLOGY (2006)
Effect of relapses on development of residual deficit in multiple sclerosis
FD Lublin et al.
NEUROLOGY (2003)